PDI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Perit Dial Int 27(6): 697-701 2007
© 2007 International Society for Peritoneal Dialysis
This Article
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ramos, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ramos, R.

Clinical

SEVELAMER HYDROCHLORIDE IN PERITONEAL DIALYSIS PATIENTS: RESULTS OF A MULTICENTER CROSS-SECTIONAL STUDY

Rosa Ramos1, Francesc Moreso1, Mercè Borras2, Esther Ponz3, Joan M. Buades4, Josep Teixidó5, Antoni Morey6, Carme Garcia7, Manel Vera8, M. Teresa Doñate9, Manuel Ramírez de Arellano10, Francesc Barbosa11, M. Teresa González1 the Catalano–Balear Peritoneal Dialysis Study Group

Servei de Nefrologia, Hospital Universitari de Bellvitge,1 L'Hospitalet, Barcelona; Hospital Arnau de Vilanova,2 Lleida; Consorci Sanitari Parc Taulí,3 Sabadell; Hospital Son LLàtzer,4 Mallorca; Hospital Germans Trias i Pujol,5 Badalona; Hospital Son Dureta,6 Mallorca; Hospital Joan XXIII,7 Tarragona; Hospital Clínic,8 Fundació Puigvert,9 Barcelona; Hospital de Terrassa,10 Terrassa; Hospital del Mar,11 Barcelona, Spain

Correspondence to: R. Ramos, Nephrology Department, Hospital Universitari de Bellvitge, C/Feixa Llarga s/n, 08907 L'Hospitalet, Barcelona, Spain. 30965rrs{at}comb.es

{diamondsuit} Background: Sevelamer hydrochloride is a phosphate binder widely employed in hemodialysis patients. Until now, information about its efficacy and safety in peritoneal dialysis patients has been scarce.

{diamondsuit} Patients and Methods: In September 2005 a cross-sectional study of demographic, biochemical, and therapeutic data of patients from 10 peritoneal dialysis units in Catalonia and the Balearic Islands, Spain, was conducted.

{diamondsuit} Results: We analyzed data from 228 patients. At the time of the study, 128 patients (56%) were receiving sevelamer. Patients receiving sevelamer were younger (p < 0.01), showed a longer period of time on dialysis (p < 0.01), and had a lower Charlson Comorbidity Index (p < 0.01). Serum calcium and intact parathyroid hormone levels were not different between the two groups, while phosphate levels <5.5 mg/dL were observed more frequently in patients not receiving sevelamer (79% vs 61%, p < 0.01). Serum total cholesterol (167 ± 41 vs 189 ± 42 mg/dL, p < 0.01) and low density lipoprotein (LDL) cholesterol (90 ± 34 vs 109 ± 34 mg/dL, p < 0.01), but not high density lipoprotein cholesterol or triglycerides, were lower in sevelamer-treated patients. Moreover, sevelamer-treated patients displayed a higher serum albumin (38 ± 5 vs 36 ± 4 g/L, p < 0.01) and a lower C-reactive protein (4.9 ± 12.8 vs 8.8 ± 15.7 mg/L, p < 0.01). Blood bicarbonate levels <22 mmol/L were observed more frequently in patients receiving sevelamer (22% vs 5%, p < 0.01). Logistic regression analysis adjusting by confounding variables confirmed that sevelamer therapy was associated with serum total cholesterol <200 mg/dL [relative risk (RR): 2.77, 95% confidence interval (CI): 1.44 – 5.26, p = 0.002] and blood bicarbonate <22 mmol/L (RR: 8.5, 95% CI: 2.6 – 27.0, p < 0.001), but not with serum phosphate >5.5 mg/dL, calcium–phosphate product >55 mg2/dL2, serum albumin <35 g/L, or C-reactive protein >5 mg/L.

{diamondsuit} Conclusions: This uncontrolled cross-sectional study in peritoneal dialysis patients showed that sevelamer hydrochloride treatment allows an adequate serum phosphate level in about 60% of patients and significantly reduces total and LDL-cholesterol levels. Since this treatment is associated with metabolic acidosis in 22% of patients, we recommend close monitoring of bicarbonate levels in this group of patients until the clinical significance of this result is clarified.

KEY WORDS: Sevelamer hydrochloride; phosphate binders.

Received 24 November 2006; accepted 18 June 2007.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Multimed Inc. logo
Copyright © 2007 by Multimed Inc.